Introduction
multiple myeloma, MM
MULTIPLE MYELOMA
The recommended standard of care in newly diagnosed multiple myeloma (NDMM) patients is induction chemotherapy, consolidation with autologous stem cell transplantation (ASCT) with high-dose melphalan conditioning if transplant-eligible, followed by maintenance [Drugs initially approved for relapsed and/or refractory MM (RRMM), like daratumumab and carfilzomib, have been introduced for the frontline treatment of NDMM to achieve higher rates of response [The data on the use of pomalidomide in NDMM is limited. We undertook the POMACE study, an open-label, single-arm, phase 2 study to evaluate the efficacy and safety of pomalidomide in NDMM.